Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Use of B-Type Natriuretic Peptide as a Prognostic Indicator in Acute Coronary Syndromes

a prognostic indicator and natriuretic peptide technology, applied in the field of bnp, can solve problems such as ischemic injury, partial or complete occlusion, and limited studies evaluating the prognostic implications of increased bnp concentration

Inactive Publication Date: 2011-03-17
DAHLEN JEFFREY R +2
View PDF90 Cites 6 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Benefits of technology

The present invention relates to materials and procedures for evaluating the prognosis of patients with acute coronary syndromes. The invention involves identifying the level of BNP (a marker related to BNP) in a patient sample and using it, alone or in combination with other markers, to predict the patient's future risk of adverse outcomes. This information can be used to guide treatment decisions for patients with acute coronary syndromes. The invention provides a valuable tool for identifying patients at risk of serious complications and improving their outcomes.

Problems solved by technology

ACS is believed to result largely from thrombus deposition and growth within one or more coronary arteries, resulting in a partial or complete occlusion of the artery, and frequently involves rupture of the plaque, resulting in an ischemic injury.
To date, however, studies evaluating the prognostic implications of increased BNP concentration have been limited to patients with ST-elevation MI, and few data are available with regard to the prognostic implications of BNP following non ST-elevation acute coronary syndromes, including unstable angina and NST-MI.

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Use of B-Type Natriuretic Peptide as a Prognostic Indicator in Acute Coronary Syndromes
  • Use of B-Type Natriuretic Peptide as a Prognostic Indicator in Acute Coronary Syndromes
  • Use of B-Type Natriuretic Peptide as a Prognostic Indicator in Acute Coronary Syndromes

Examples

Experimental program
Comparison scheme
Effect test

example 1

Validation of BNP as a Prognostic Indicator in ACS

Study Population

[0057]The Oral Glycoprotein IIb / IIIa Inhibition with Orbofiban in Patients with Unstable Coronary Syndromes (OPUS-TIMI 16) Trial was a randomized multicenter trial comparing an oral glycoprotein IIb / IIIa inhibitor, orbofiban, with placebo in 10,288 patients with acute coronary syndromes. Patients were included if they presented within 72 hours of the onset of ischemic discomfort and met one or more of the following criteria: dynamic ECG changes (ST deviation 0.5 mm, T-mm, T-wave inversion 3 mm in 3 leads, or left bundle branch block); positive cardiac markers; prior history of coronary artery disease; or age 65 with evidence of diabetes or vascular disease. See, e.g., Cannon et al., Circulation 102: 149-56 (2000).

[0058]The study population described in the Examples herein consisted of a subpopulation of 2525 patients from the OPUS-TIMI 16 study, of whom 825 were enrolled following an index ST elevation MI, 565 followi...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

PropertyMeasurementUnit
concentrationaaaaaaaaaa
concentrationaaaaaaaaaa
concentrationaaaaaaaaaa
Login to View More

Abstract

The present invention relates to materials and procedures for evaluating the prognosis of patients suffering from acute coronary syndromes. In particular, the level of BNP, or a marker related to BNP, in a patient sample, alone or in combination with one or more other prognostic markers, provides prognostic information useful for predicting near-term morbidity and / or mortality across the entire spectrum of acute coronary syndromes, including unstable angina, non-ST-elevation non-Q wave myocardial infarction, ST-elevation non-Q wave MI, and transmural (Q-wave) MI.

Description

[0001]This application is a divisional of U.S. patent application Ser. No. 09 / 835,298 (pending), filed Apr. 13, 2001.FIELD OF THE INVENTION[0002]The present invention relates in part to methods, compositions, and devices for the measurement of BNP, and the use of such measurement in the diagnosis, prognosis, and treatment of patients with acute coronary syndromes.BACKGROUND OF THE INVENTION[0003]The following discussion of the background of the invention is merely provided to aid the reader in understanding the invention and is not admitted to describe or constitute prior art to the present invention.[0004]The term “acute coronary syndromes” (“ACS”) has been applied to a group of coronary disorders that result from ischemic insult to the heart. Patients with ACS form a heterogeneous group, with differences in pathophysiology, clinical presentation, and risk for adverse events. Such patients present to the physician with conditions that span a continuum that includes unstable angina,...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Applications(United States)
IPC IPC(8): G01N33/566G01N33/53C07K14/575G01N33/68
CPCG01N33/6887G01N2800/324G01N2333/58G01N33/6893
Inventor DAHLEN, JEFFREY R.BUECHLER, KENNETH F.VALKIRS, GUNARS E.
Owner DAHLEN JEFFREY R
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com